Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for #Alzheimer’s disease and expand into immune diseases. The Series B was led by Korean venture capital firm DSC Investment, whose portfolio includes billionaire Chung Yong-ji’s #biotech company Caregen. Other investors include local venture capital firms Aju IB Investment, IMM Investment, LB Investment and GS Ventures, the venture capital arm of conglomerate GS Group. The Series B round brings the startup’s total funding raised to $63 million. Illimis Therapeutics was established in 2021 by ex-venture capitalist Park Sanghoon, as well as biological sciences professors Chung Wonsuk and Kim Chanhyuk. The biotech #startup focuses on treatments for Alzheimer’s disease, the leading cause of #dementia in the elderly. Tap the link in our bio to read more.